Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept pharmacologic treatment study in congenital nephrogenic diabetes insipidus
2006-003360-56Phase 2Terminated
- Sponsor
- Children's Hospital Colorado
- Start
- Jul 2009
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of sildenafil and TBRIA in congenital arginine vasopressin resistance (cAVP-R) (2 arms), sponsored by Children's Hospital Colorado. Primary endpoints: 24-hour urine volume, Treatment effect on 24-hour urine production versus baseline and 1 more. Started Jul 2009; status: terminated.
02
Drugs
sildenafilTBRIA
03
Conditions
congenital arginine vasopressin resistance (cAVP-R)
Beyond the preview
Go deeper on 2006-003360-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003360-56.